Ara
Toplam kayıt 9, listelenen: 1-9
Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer
(Elsevier Science Inc, 2019)
The significance of the presence of a systemic inflammatory response (SIR) in predicting survival has been demonstrated in patients with cancer. Moreover, neutrophil-to-lymphocyte ratio (NLR), lymphocyteratio (NLR), ...
The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey
(Amer Assoc Cancer Research, 2019)
Background: Endocrine treatment and chemotherapy are a treatment options for patients with hormone receptor (HR) positive and HER2-negative metastatic breast cancer (MBC). However, response to first-line hormone treatment ...
Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
(Oxford University Press, 2019)
Background The prognostic importance of platelet-to-lymphocyte ratio(PLR)has been also investigated in some cancer types including colorectal cancer (CRC).Several studies have found that PLR is associated with poor prognosis ...
Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
(Oxford University Press, 2019)
Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who ...
Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?
(Elsevier Science, 2019)
Background: Approximately 5% of all diagnosed non-small cell lung cancer (NSCLC) patients harbor a genetic rearrangement between the ALK and EML4 genes, representing a specific molecular and clinical subgroup (ALK+ NSCLC). ...
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
(Elsevier Science, 2019)
Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ...
Metastatik meme kanseri tedavisinde lapatinib kapesitabin kombinasyonun etkinliğinin retrospektif değerlendirilmesi
(2019)
Tüm dünyada meme kanseri kadınlarda kanserin ve kanser ilişkili ölümlerin en sık nedenidir. Meme kanserli hastaların %17-30 HER2overekspresyonu olup hastalık, kötü prognoz, hastalık progresyon riskinde artış, genel sağkalım ...
Prognostic significance of metastatic lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectom
(Karger, 2019)
Background: Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) and compare it ...
Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade
(SAGE Publications Ltd, 2019)
Paraneoplastic neurological syndrome is associated with anti-Ri antibodies, which are typically present with opsoclonus–myoclonus–ataxia. Human epidermal growth factor receptor 2 (HER2) overexpression is present in 15%–25% ...